| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,920,000 |
| Market
Cap: |
1.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.43 - $23.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 31.4 |
| Insider 6 Months : 31.4 |
| Insider 3/6 Months : 63.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,238,095 |
15,238,095 |
16,248,095 |
16,248,095 |
| Total Buy Value |
$319,999,995 |
$319,999,995 |
$339,452,595 |
$339,452,595 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
2 |
2 |
| Total Shares Sold |
110,657 |
141,439 |
237,875 |
329,459 |
| Total Sell Value |
$2,164,815 |
$2,731,452 |
$4,652,676 |
$7,003,905 |
| Total People Sold |
2 |
4 |
4 |
6 |
| Total Sell Transactions |
6 |
10 |
16 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kaneko Yasunori |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
6,800 |
|
- |
|
| Lambert Nicole |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
15,600 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
46,900 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2023-06-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
50,504 |
40,100 |
|
- |
|
| Lacey David L. |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
49,252 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2023-06-07 |
4 |
AS |
$20.04 |
$81,142 |
D/D |
(4,049) |
59,392 |
|
-21% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-03-16 |
4 |
S |
$16.81 |
$146,734 |
D/D |
(8,729) |
406,217 |
|
-15% |
|
| Azoy Alexander |
Chief Accounting OfficerOffice |
• – – |
2023-03-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,596 |
|
19% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-01-27 |
4 |
AS |
$23.52 |
$37,632 |
D/D |
(1,600) |
414,946 |
|
-11% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-01-26 |
4 |
AS |
$23.56 |
$7,068 |
D/D |
(300) |
416,546 |
|
-13% |
|
| Nuyten Dimitry Sa |
Chief Medical Officer |
• – – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
76,500 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
105,700 |
469,123 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
63,441 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
45,800 |
324,682 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
97,539 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
45,800 |
416,846 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2022-12-16 |
4 |
S |
$30.66 |
$506,822 |
D/D |
(16,482) |
147,609 |
|
42% |
|
| Jaen Juan C. |
President |
• • – |
2022-12-16 |
4 |
S |
$30.66 |
$136,407 |
D/D |
(4,436) |
218,258 |
|
42% |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2022-12-16 |
4 |
S |
$30.66 |
$75,430 |
D/D |
(2,453) |
11,566 |
|
42% |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2022-12-16 |
4 |
S |
$30.66 |
$401,073 |
D/D |
(13,043) |
242,173 |
|
42% |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2022-12-16 |
4 |
S |
$30.66 |
$77,582 |
D/D |
(2,523) |
28,584 |
|
42% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2022-09-16 |
4 |
S |
$26.28 |
$333,152 |
D/D |
(12,677) |
130,942 |
|
14% |
|
| Nuyten Dimitry Sa |
Chief Medical Officer |
• – – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
42,500 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2022-06-17 |
4 |
S |
$21.71 |
$56,116 |
D/D |
(2,537) |
210,037 |
|
-31% |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2022-06-17 |
4 |
S |
$21.71 |
$33,665 |
D/D |
(1,522) |
23,909 |
|
-31% |
|
207 Records found
|
|
Page 3 of 9 |
|
|
0.08 (0.51%) 
